Knight Therapeutics (TSE:GUD) Reaches New 12-Month High – What’s Next?

Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high during trading on Thursday . The stock traded as high as C$8.04 and last traded at C$7.86, with a volume of 37887 shares. The stock had previously closed at C$7.51.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$9.50 target price on Knight Therapeutics and gave the stock a “buy” rating in a research note on Friday. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of C$9.50.

Knight Therapeutics Price Performance

The company has a current ratio of 2.32, a quick ratio of 1.79 and a debt-to-equity ratio of 8.86. The company has a 50 day moving average price of C$7.03 and a 200 day moving average price of C$6.36. The company has a market capitalization of C$852.11 million, a P/E ratio of -173.80, a P/E/G ratio of -1,013.50 and a beta of -0.21.

Knight Therapeutics (TSE:GUD) last issued its earnings results on Thursday, May 7th. The company reported C$0.13 EPS for the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%.The company had revenue of C$147.59 million during the quarter. On average, equities analysts predict that Knight Therapeutics Inc. will post 0.1009486 EPS for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.